Evogene Ltd. (NASDAQ:EVGN) Short Interest Update

Evogene Ltd. (NASDAQ:EVGNGet Free Report) was the target of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 135,100 shares, an increase of 503.1% from the October 31st total of 22,400 shares. Based on an average daily volume of 272,900 shares, the short-interest ratio is currently 0.5 days. Currently, 2.6% of the shares of the stock are sold short.

Institutional Investors Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC acquired a new stake in Evogene Ltd. (NASDAQ:EVGNFree Report) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is currently owned by institutional investors and hedge funds.

Evogene Stock Down 4.6 %

Shares of EVGN stock traded down $0.08 during trading hours on Friday, reaching $1.61. 40,963 shares of the stock traded hands, compared to its average volume of 89,044. Evogene has a 1-year low of $1.44 and a 1-year high of $10.40. The business has a fifty day moving average price of $2.27 and a 200 day moving average price of $4.29.

Analyst Ratings Changes

Several research firms recently commented on EVGN. Lake Street Capital cut their target price on shares of Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, August 23rd. StockNews.com began coverage on shares of Evogene in a research note on Tuesday. They set a “sell” rating for the company.

View Our Latest Analysis on EVGN

Evogene Company Profile

(Get Free Report)

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.

Read More

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.